转移性激素敏感性前列腺癌内脏转移患者的治疗疗效:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入8项III期随机对照试验(共7944例,其中1189例伴内脏转移),评估mHSPC内脏转移亚组的总生存获益。结果示ADT+多西他赛+达罗他胺三联方案OS获益最大(HR=0.42,95%CI 0.21-0.82),双药中ADT+多西他赛与ADT+阿比特龙优于其他ARPI双药。
要点
- ADT+多西他赛+达罗他胺三联为内脏转移mHSPC OS获益最大方案。
- 双药中ADT+多西他赛(HR=0.53)与ADT+阿比特龙(HR=0.58)优于其他ARPI双药。
- 缺乏个体患者数据及按转移部位分层的疗效数据为主要局限。
核心结论
- 对于伴内脏转移的mHSPC患者,ADT+多西他赛+达罗他胺三联强化治疗提供最大OS获益。
- 含化疗或阿比特龙的双药方案仍是可行的替代选择。
研究设计与样本
- 系统综述与网络Meta分析,遵循PRISMA指南(PROSPERO: CRD42025642120)。
- 检索PubMed、Cochrane和Embase数据库,纳入报告内脏转移患者OS的III期随机对照试验。
- 共纳入8项III期试验,7944例患者,其中1189例伴内脏转移。
- 采用频率学网络Meta分析框架,提取HR和95%CI,并使用CINeMA工具评估偏倚风险。
主要发现
- ADT+多西他赛+达罗他胺组合最有效(HR=0.42,95%CI: 0.21-0.82)。
- 双药方案中,ADT+多西他赛(HR=0.53,95%CI: 0.30-0.93)和ADT+阿比特龙(HR=0.58,95%CI: 0.41-0.83)疗效优于其他ARPI双药(包括恩扎卢胺、阿帕他胺、达罗他胺联合方案)。
关键数值与推荐
- ADT+多西他赛+达罗他胺:HR=0.42,95%CI: 0.21-0.82。
- ADT+多西他赛:HR=0.53,95%CI: 0.30-0.93。
- ADT+阿比特龙:HR=0.58,95%CI: 0.41-0.83。
临床怎么用
- 对伴内脏转移的mHSPC患者,可优先考虑ADT+多西他赛+达罗他胺三联强化治疗。
- 若不适合三联,含多西他赛或阿比特龙的双药方案可作为替代。
- 治疗选择需结合内脏转移具体部位(肝或肺)进一步个体化。
局限性
- 缺乏个体患者数据。
- 缺乏按转移部位(肝或肺受累)分层的疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Metastatic hormone-sensitive prostate cancer (mHSPC) patients with visceral disease (VD) represent a high-risk subgroup associated with poor prognosis. Despite the introduction of treatment intensification strategies, the optimal systemic therapy for these patients remains unclear. This network meta-analysis (NMA) aims to evaluate the efficacy of the current therapeutic combinations in terms of overall survival (OS) in the subgroup of patients with VD. METHODS: A systematic review and NMA was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (PROSPERO: CRD42025642120). Phase 3 randomised controlled trials assessing systemic therapies for mHSPC were identified through the PubMed, Cochrane, and Embase databases. Only studies reporting OS outcomes for patients with VD were included. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and analysed using a frequentist NMA framework. The risk of bias was assessed using the Confidence in Network Meta-Analysis (CINeMA) tool. KEY FINDINGS AND LIMITATIONS: Eight phase 3 trials (7944 patients, 1189 with VD) were included. The androgen deprivation therapy (ADT) + docetaxel + darolutamide combination was the most effective regimen (HR = 0.42, 95% CI: 0.21-0.82). Among doublets, ADT + docetaxel (HR = 0.53, 95% CI: 0.30-0.93) and ADT + abiraterone (HR = 0.58, 95% CI: 0.41-0.83) showed superior efficacy to other androgen receptor pathway inhibitor-based doublet regimens, including combinations with enzalutamide, apalutamide, and darolutamide. The absence of individual patient data and the lack of efficacy data stratified by metastatic site (liver or lung involvement) were the key limitations. CONCLUSIONS AND CLINICAL IMPLICATIONS: Treatment intensification with triplet therapy (ADT + docetaxel + darolutamide) provides the greatest OS benefit in mHSPC patients with VD. Doublet regimens incorporating chemotherapy or abiraterone remain viable alternatives. Further prospective studies are needed to refine treatment selection based on VD-specific biology and organ-specific metastatic patterns.
引用
- Flauto F, Neola G, Caso C, et al. Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2025. PMID: 40645821. doi:10.1016/j.euo.2025.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。